{
  "symbol": "VRTX",
  "year": 2023,
  "competition_summary": [
    {
      "competitor": "Medicare",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "TRIKAFTA",
      "mentions": 8,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "KAFTRIO",
      "mentions": 5,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "CF",
      "mentions": 9,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Concert Pharmaceuticals Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Semma",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "IND",
      "mentions": 3,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "DMD",
      "mentions": 3,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "ViaCyte",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Catalyst Biosciences, Inc.\u2019s",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "SCD",
      "mentions": 5,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "TDT",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Original JDCA",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "CRISPR",
      "mentions": 9,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the Original JDCA",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the A&R JDCA",
      "mentions": 11,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "FDA",
      "mentions": 7,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the European Commission",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "\u2022 CRISPR Therapeutics AG",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Entrada",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "EEV",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Verve Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Obsidian Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Mammoth Biosciences, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Affinia Therapeutics, Inc and Skyhawk Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Ribometrix, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Kymera Therapeutics",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Cystic Fibrosis Foundation",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the Cystic Fibrosis Foundation",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the Cystic Fibrosis Foundation Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "ORKAMBI",
      "mentions": 4,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "a New Drug Application",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "NDA",
      "mentions": 3,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the Orange Book",
      "mentions": 4,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "KALYDECO",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "SYMDEKO/SYMKEVI",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "U.S. Basic Product Patent Expiration Year",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "SYMKEVI",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "AATD",
      "mentions": 2,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the University of California or",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the University of Vienna",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the CVC Group",
      "mentions": 4,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Trademark Office",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "the Broad Institute",
      "mentions": 3,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "LLC",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "ToolGen, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "inter partes",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "COVID-19",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "CRISPR/Cas9",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "CFTR",
      "mentions": 3,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Phase 2",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Proteostasis Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Yumanity Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Fair Therapeutics",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Arcturus Therapeutics Holdings, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "ReCode Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Krystal Biotech, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Spirovant Sciences",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Boehringer Ingelheim International",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "GmbH",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "4D Molecular Therapeutics, Inc and",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Novartis International AG",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Global Blood Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Bristol Myers Squibb",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Merck & Co.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "bio, Inc.",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "BLA",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Orion Corporation",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Luzsana Biotechnology",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Additional Programs Certain",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Ionis Pharmaceuticals",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Eli Lilly and Company\u2019s Janus",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    },
    {
      "competitor": "Duke University",
      "mentions": 1,
      "context": "competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part\u00a0D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement. In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed b"
    }
  ]
}